REGENERON PHARMACEUTICALS, INC. Increase (Decrease) in Restricted Cash and Investments
REGENERON PHARMACEUTICALS, INC. (REGN) reported Increase (Decrease) in Restricted Cash and Investments of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments · last filed 2014-02-13
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for the quarter ending 2013-03-31 was $314.00K, a 32.18% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for the quarter ending 2012-12-31 was $34.00K.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for the quarter ending 2012-09-30 was $49.00K, a 1125.00% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for the quarter ending 2012-06-30 was $6.00K, a 99.16% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for fiscal 2012 was $552.00K, a 99.28% increase from fiscal 2011.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for fiscal 2011 was $277.00K, a 95.34% decline from fiscal 2010.
- REGENERON PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for fiscal 2010 was $5.94M.
| Period end | Increase (Decrease) in Restricted Cash and Investments 3 month | Increase (Decrease) in Restricted Cash and Investments 6 month | Increase (Decrease) in Restricted Cash and Investments 9 month | Increase (Decrease) in Restricted Cash and Investments 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-13 | |||
| 2013-03-31 | $314.00K 10-Q · filed 2013-05-03 | $348.00K derived: sum of 2 quarters · filed 2014-02-13 | $397.00K derived: sum of 3 quarters · filed 2014-02-13 | $403.00K derived: sum of 4 quarters · filed 2014-02-13 |
| 2012-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $83.00K derived: sum of 2 quarters · filed 2014-02-13 | $89.00K derived: sum of 3 quarters · filed 2014-02-13 | $552.00K 10-K · filed 2014-02-13 |
| 2012-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $55.00K derived: sum of 2 quarters · filed 2013-11-05 | $518.00K 10-Q · filed 2013-11-05 | $110.00K derived: sum of 4 quarters · filed 2014-02-13 |
| 2012-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $469.00K 10-Q · filed 2013-08-06 | $61.00K derived: sum of 3 quarters · filed 2014-02-13 | $65.00K derived: sum of 4 quarters · filed 2014-02-13 |
| 2012-03-31 | $463.00K 10-Q · filed 2013-05-03 | $55.00K derived: sum of 2 quarters · filed 2014-02-13 | $59.00K derived: sum of 3 quarters · filed 2014-02-13 | $772.00K derived: sum of 4 quarters · filed 2014-02-13 |
| 2011-12-31 | -$408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | -$404.00K derived: sum of 2 quarters · filed 2014-02-13 | $309.00K derived: sum of 3 quarters · filed 2014-02-13 | $277.00K 10-K · filed 2014-02-13 |
| 2011-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $717.00K derived: sum of 2 quarters · filed 2012-10-24 | $685.00K 10-Q · filed 2012-10-24 | |
| 2011-06-30 | $713.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $681.00K 10-Q · filed 2012-07-25 | ||
| 2011-03-31 | -$32.00K 10-Q · filed 2012-04-26 | |||
| 2010-12-31 | $5.94M 10-K · filed 2013-02-15 | |||
| 2009-12-31 | -$50.00K 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |